BECHTELSVILLE, Pennsylvania (WPVI) -- Most of us take breathing for granted. But with pulmonary fibrosis, patients lose that despite the best medical efforts. That outcome is on the verge of change.

Because evidence gaps in idiopathic pulmonary fibrosis research hinder demonstration of antifibrotic therapies’ impact on patient quality of life (QOL), integrating validated health-related QOL ...

Panelists discuss how managing idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF) requires a comprehensive, patient-centered approach that addresses not only physiological ...

Please provide your email address to receive an email when new articles are posted on . Researchers found differences between the two settings when evaluating the number of patients who agreed with ...